Psychiatry and Neurology, Neurology · Coral Springs, FL
NPI
1023231883
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
5441 N University Dr Ste 101
Coral Springs, FL, 33067
Phone (954) 803-9002
Groups this clinician bills Medicare through
Medicare paid, 2024
$566K
14,300 services
Medicare patients, 2024
771
Average age 76
Drug cost, 2024
$8.2M
13,265 prescriptions
Company payments, 2025
$7,401
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ivan Mikolaenko was code J0585 (injection, onabotulinumtoxina, 1 unit), 6,950 times for 17 patients. In total Ivan Mikolaenko billed 14,300 services in 59 codes, and Medicare paid $566K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 6,950 | 17 | $4.98 | $35K |
| 99213 Office E&M - Established | Office | 945 | 480 | $85.45 | $81K |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 783 | 255 | $0.43 | $338 |
| 96374 Injection Administration | Office | 687 | 253 | $36.10 | $25K |
| 99214 Office E&M - Established | Office | 619 | 349 | $121.39 | $75K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 516 | 134 | $60.52 | $31K |
| 95886 Electrical Nerve Conductivity | Office | 424 | 207 | $93.73 | $40K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 284 | 65 | $0.50 | $142 |
| 96372 Injection Administration | Office | 272 | 130 | $13.96 | $3,798 |
| 96375 Injection Administration | Office | 221 | 82 | $15.13 | $3,344 |
| 95911 Electrical Nerve Conductivity | Office | 216 | 207 | $205.45 | $44K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 202 | 81 | $46.68 | $9,430 |
| 99204 Office E&M - New | Office | 168 | 168 | $161.97 | $27K |
| 95992 Treatment - Miscellaneous | Office | 135 | 76 | $39.98 | $5,397 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 130 | 55 | $0.98 | $127 |
By year: 2022 $141K for 3,007 services; 2023 $398K for 10,884 services; 2024 $566K for 14,300 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 16 | 15 | $8.40 | $134 |
Medicare prescription drug claims, 2024
In 2024, the drug Ivan Mikolaenko prescribed most often to Medicare patients was Diclofenac Sodium, with 1,314 prescriptions and refills. In total Ivan Mikolaenko wrote 13,265 Medicare prescriptions that cost $8.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diclofenac Sodium Generic | 1,314 | 1,355 | 264 | $1.3M |
| Ztlido Lidocaine | 923 | 931 | 202 | $319K |
| Nurtec Odt Rimegepant Sulfate | 913 | 926 | 159 | $1.6M |
| Gabapentin Generic | 789 | 866 | 222 | $3,165 |
| Diclofenac Potassium Generic | 748 | 751 | 154 | $1.8M |
| Diclofenac Epolamine Generic | 681 | 683 | 157 | $216K |
| Duloxetine Hcl Generic | 415 | 466 | 97 | $4,711 |
| Meclizine Hcl Generic | 396 | 398 | 130 | $1,503 |
| Memantine Hcl Er Memantine Hcl | 373 | 397 | 88 | $27K |
| Dihydroergotamine Mesylate Generic | 330 | 330 | 60 | $373K |
| Rexulti Brexpiprazole | 266 | 266 | 47 | $375K |
| Meloxicam Generic | 251 | 259 | 142 | $278 |
| Namzaric Memantine Hcl/Donepezil Hcl | 241 | 251 | 52 | $148K |
| Amitriptyline Hcl Generic | 236 | 250 | 67 | $732 |
| Horizant Gabapentin Enacarbil | 185 | 187 | 50 | $107K |
Brand drugs: 5,291 claims; generic drugs: 7,974 claims; opioid claims: 194.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ivan Mikolaenko $7,401 ($7,401 in general payments such as food, travel and fees) from 39 companies. The largest payer was Abbvie Inc. with $1,581.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 52 | $1,581 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 16 | $673 |
| Axsome Therapeutics, Inc. AXSM | 16 | $431 |
| SK Life Science, Inc. | 16 | $428 |
| Pfizer Inc. PFE | 18 | $402 |
| UCB, Inc. UCB.BR | 28 | $402 |
| Lundbeck LLC | 14 | $370 |
| Amneal Pharmaceuticals LLC AMRX | 7 | $233 |
| Harmony Biosciences LLC HRMY | 12 | $230 |
| Neurelis, Inc. | 8 | $218 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.